X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
tadalafil (1390) 1390
male (863) 863
humans (838) 838
index medicus (800) 800
erectile dysfunction (624) 624
urology & nephrology (509) 509
sildenafil (506) 506
middle aged (470) 470
erectile dysfunction - drug therapy (443) 443
impotence (363) 363
sildenafil citrate (346) 346
treatment outcome (337) 337
carbolines - therapeutic use (324) 324
adult (321) 321
aged (300) 300
men (283) 283
vardenafil (261) 261
phosphodiesterase 5 inhibitors - therapeutic use (248) 248
efficacy (241) 241
double-blind (234) 234
animals (222) 222
phosphodiesterase inhibitors - therapeutic use (212) 212
safety (187) 187
double-blind method (182) 182
carbolines - administration & dosage (181) 181
drug therapy (180) 180
research (172) 172
care and treatment (171) 171
female (170) 170
analysis (160) 160
pharmacology & pharmacy (159) 159
benign prostatic hyperplasia (156) 156
phosphodiesterase 5 inhibitors - administration & dosage (148) 148
carbolines - pharmacology (142) 142
vardenafil dihydrochloride (137) 137
prostate (136) 136
carbolines - adverse effects (135) 135
rats (132) 132
piperazines - therapeutic use (131) 131
dosage and administration (128) 128
sexual disorders (118) 118
therapy (118) 118
nitric-oxide (117) 117
pulmonary hypertension (117) 117
urology (115) 115
phosphodiesterase 5 inhibitors - pharmacology (114) 114
penile erection - drug effects (113) 113
hypertension (111) 111
phosphodiesterase 5 inhibitors (109) 109
lower urinary tract symptoms (108) 108
dose-response relationship, drug (107) 107
phosphodiesterase inhibitors - administration & dosage (107) 107
sulfones - therapeutic use (105) 105
drug administration schedule (104) 104
erectile dysfunction - etiology (103) 103
phosphodiesterase inhibitors - adverse effects (103) 103
clinical trials (101) 101
hypertrophy (96) 96
patient satisfaction (92) 92
tadalafil - therapeutic use (92) 92
inhibitors (90) 90
drug therapy, combination (88) 88
hypertension, pulmonary - drug therapy (88) 88
medicine & public health (87) 87
phosphodiesterase inhibitors - pharmacology (85) 85
surveys and questionnaires (83) 83
international index (82) 82
nitric oxide (82) 82
phosphodiesterase (81) 81
health aspects (80) 80
phosphodiesterase 5 inhibitors - adverse effects (80) 80
purines - therapeutic use (80) 80
young adult (79) 79
erectile dysfunction - physiopathology (78) 78
phosphodiesterase type 5 inhibitors (76) 76
prostatic hyperplasia - complications (76) 76
time factors (75) 75
sexual dysfunction (74) 74
imidazoles - therapeutic use (72) 72
pde5 inhibitors (72) 72
tamsulosin (72) 72
urinary-tract symptoms (72) 72
dysfunction (70) 70
risk factors (70) 70
tadalafil - administration & dosage (69) 69
complications and side effects (68) 68
phosphodiesterase inhibitors (68) 68
prevalence (68) 68
drugs (67) 67
vasodilator agents - therapeutic use (67) 67
prospective studies (66) 66
andrology (65) 65
cyclic nucleotide phosphodiesterases, type 5 (65) 65
disease models, animal (65) 65
prostatic hyperplasia - drug therapy (65) 65
quality of life (65) 65
cardiac & cardiovascular systems (64) 64
medical research (64) 64
piperazines - pharmacology (64) 64
triazines - therapeutic use (64) 64
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1462) 1462
Chinese (17) 17
Japanese (8) 8
Russian (8) 8
Spanish (8) 8
French (7) 7
German (7) 7
Italian (2) 2
Czech (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Clinical Practice, ISSN 1368-5031, 08/2012, Volume 66, Issue 8, pp. 813 - 820
...) as well as safety of tadalafil dosed at 20 mg on‐demand and 5 mg once daily among ED patients... 
BENIGN PROSTATIC HYPERPLASIA | TRIAL | WOMEN | MEDICINE, GENERAL & INTERNAL | THERAPY | ASIAN MEN | SAFETY | SECONDARY | INHIBITORS | EAST | PARTNERS | Tadalafil | Medical colleges | Care and treatment | Heart beat | Impotence | Comparative analysis | Personal video recorders
Journal Article
European Urology, ISSN 0302-2838, 08/2006, Volume 50, Issue 2, pp. 351 - 359
...:2 to placebo, tadalafil 5 mg, and tadalafil 10 mg taken once daily. Primary efficacy measures included changes in the International Index of Erectile Function Erectile Function domain (IIEF EF... 
Tadalafil | Erectile dysfunction | Once-a-day dosing | once-a-day dosing | tadalafil | SILDENAFIL | TOLERABILITY | MEN | UROLOGY & NEPHROLOGY | DEMAND TADALAFIL | erectile dysfunction
Journal Article
Journal Article
Therapeutic Advances in Urology, ISSN 1756-2872, 12/2018, Volume 10, Issue 12, pp. 377 - 381
...) guidelines were evaluated for once-daily 5 mg tadalafil; 14 patients were eligible for the study... 
chronic pelvic pain syndrome | chronic prostatitis | tadalafil | NITRIC-OXIDE | UROLOGY & NEPHROLOGY | Prostate | Pain | Quality of life
Journal Article
LUTS: Lower Urinary Tract Symptoms, ISSN 1757-5664, 01/2018, Volume 10, Issue 1, pp. 84 - 92
Journal Article
WORLD JOURNAL OF MENS HEALTH, ISSN 2287-4208, 05/2018, Volume 36, Issue 2, pp. 161 - 170
Purpose: The aim of this study was to investigate the safety and effectiveness of tadalafil 5 mg once daily (quaque die [everyday], QD... 
MANAGEMENT | EFFICACY | ANDROLOGY | 12-WEEK | Phosphodiesterase 5 Inhibitors | SECONDARY | TAMSULOSIN | COMBINATION | GUIDELINE | Tadalafil | ASIAN MEN | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | Prostatic hyperplasia | Safety | INHIBITORS | Lower urinary tract symptoms | Original | 비뇨기과학
Journal Article
Journal Article